Tezepelumab helps severe asthma patients reduce oral steroids over 28 weeks

A Phase III clinical trial called SUNRISE demonstrates that tezepelumab significantly reduces the need for long-term oral corticosteroids in adults with severe oral corticosteroid-dependent asthma. The medication maintained asthma control while improving key clinical outcomes over a 28-week period. These findings, published in The Lancet Respiratory Medicine, offer hope for patients who rely heavily on oral steroids, as reducing steroid dependence can minimize serious side effects associated with long-term corticosteroid use. This breakthrough treatment represents an important advance in managing severe, difficult-to-control asthma.